BOLD
INSIDER BUYINSIDER SELLBoundless Bio, Inc.
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
News Summary
NegativeBoundless Bio announced a transformative all-stock merger with Serapha Bio (June 2026), effectively pivoting from its original oncology portfolio to a gene-editing focused biotech company, with the combined entity expected to close in Q4 2026 and focus on SERP-01 for Alpha-1 Antitrypsin Deficiency. Pre-merger Boundless shareholders will own only ~3.7% of the combined company post-closing, with a $44-48M special dividend offsetting dilution. The lead BBI-940 program (oral kinesin degrader) entered Phase 1 for breast cancer, though analyst coverage has thinned and the company's strategic direction has fundamentally shifted.
Red flags
- •Extreme shareholder dilution: pre-merger BOLD shareholders own only ~3.7% of combined entity post-merger
- •All-stock merger structure indicates BOLD negotiated from position of weakness; no cash consideration for shareholders
- •Analyst coverage collapsed to 'Neutral' consensus with no buy recommendations; only 2-3 analysts maintaining sparse coverage
- •Complete strategic pivot away from original pipeline (ecDNA oncology) suggests prior strategy failure or capital constraints
- •Lead asset BBI-940 still in early Phase 1; no clinical proof-of-concept data yet; merger dependent on unproven gene-editing platform (SERP-01)
- •Q1 2026 cash of $92.8M with $14.5M quarterly burn rate leaves limited runway independent of merger financing
- •Merger contingent on Q4 2026 close with stockholder approval requirement; deal risk and uncertainty extends through year-end
Insider Activity
| Name | Title | Type | Shares | Price | Value | Filed | Src |
|---|---|---|---|---|---|---|---|
| TANG KEVIN | — | BUY | 3K | $2.44 | $0.01M | 2026-07-21 | ↗ |
| TANG KEVIN | — | BUY | 2K | $2.44 | $0.00M | 2026-07-20 | ↗ |
| TANG KEVIN | — | BUY | 265 | $2.44 | $0.00M | 2026-07-17 | ↗ |
| TANG KEVIN | — | BUY | 18K | $2.44 | $0.05M | 2026-07-16 | ↗ |
| TANG KEVIN | — | BUY | 2K | $2.44 | $0.00M | 2026-07-15 | ↗ |
| TANG KEVIN | — | BUY | 44K | $2.43 | $0.11M | 2026-07-14 | ↗ |
| TANG KEVIN | — | BUY | 48K | $2.42 | $0.12M | 2026-07-13 | ↗ |
| TANG KEVIN | — | BUY | 43K | $2.43 | $0.11M | 2026-07-10 | ↗ |
| TANG KEVIN | — | BUY | 7 | $2.48 | $0.00M | 2026-07-09 | ↗ |
| TANG KEVIN | — | BUY | 14K | $2.46 | $0.04M | 2026-07-08 | ↗ |
| TANG KEVIN | — | BUY | 16K | $2.48 | $0.04M | 2026-07-07 | ↗ |
| TANG KEVIN | — | BUY | 27K | $2.49 | $0.07M | 2026-07-06 | ↗ |
| TANG KEVIN | — | BUY | 10K | $2.49 | $0.02M | 2026-07-02 | ↗ |
| CRANDELL KEITH | — | SELL | 16K | $2.49 | $0.04M | 2026-07-01 | ↗ |
| ARCH Venture Fund IX, L.P. | — | SELL | 16K | $2.49 | $0.04M | 2026-07-01 | ↗ |
| TANG KEVIN | — | BUY | 72K | $2.49 | $0.18M | 2026-07-01 | ↗ |
| TANG KEVIN | — | BUY | 26K | $2.54 | $0.07M | 2026-06-30 | ↗ |
| TANG KEVIN | — | BUY | 100 | $2.50 | $0.00M | 2026-06-30 | ↗ |
Fund 13D/13G Filings (1)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).
| Fund | Form | ∆ Shares | % of Class | Since Filing | Filed | Src |
|---|---|---|---|---|---|---|
| Citadel Advisors | SC 13G/A | — | 0.6% | +4.2% vs SPY +2.5% abs | 2026-08-14 | ↗ |